Q3 2024 ReportResults in line for Q3 2024 with sales momentum increasing throughout the period and into Q4GIG Software Plc ...

TPEIR: Piraeus increases its net profit in Q3 by 15% yoy, to €320mn Q3 9M 2024 highlights Record 9M normalized net profit of €932mn, corresponding to €0.72 EPS, leading to updated target of >€0.90 for ...

Moderna (MRNA) is up more than +3% after reporting Q3 Covid-19 vaccine revenue of $1.8 billion, which is stronger than the consensus of $1.2 billion. Lyft (LYFT) is up more than +29% after reporting ...

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

Although the revenue and EPS for Moderna (MRNA) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall ...

Moderna ( (MRNA) ) has released its Q3 earnings. Here is a breakdown of the information Moderna presented to its investors. Moderna, Inc. is a ...

Moderna (MRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Tyler Van Buren ...

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

Moderna reported better third-quarter results than expected Thursday morning, as the vaccine maker reported a surprise profit ...